Veracyte VCYT Biopharmaceutical revenue — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Veracyte's biopharmaceutical revenue — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Veracyte's biopharmaceutical revenue — total revenue?
- Veracyte (VCYT) reported biopharmaceutical revenue — total revenue of $301K in Q1 2026.
- How has Veracyte's biopharmaceutical revenue — total revenue changed year-over-year?
- Veracyte's biopharmaceutical revenue — total revenue decreased by 86.9% year-over-year, from $2.3M to $301K.
- What is the long-term trend for Veracyte's biopharmaceutical revenue — total revenue?
- Over 4 years (2021 to 2025), Veracyte's biopharmaceutical revenue — total revenue has grown at a -15.2% compound annual growth rate (CAGR), from $12.61M to $6.54M.
- What does biopharmaceutical revenue — total revenue mean?
- This metric represents the total revenue generated from services and collaborations provided to biopharmaceutical partners, such as clinical trial support or companion diagnostic development. It reflects the company's ability to monetize its proprietary diagnostic platforms through B2B partnerships rather than direct clinical testing. Tracking this revenue stream helps investors assess the company's diversification beyond core clinical diagnostic volumes and its integration into the broader drug development ecosystem.